Mitochondria in chemotherapy-induced apoptosis: A prospective novel target of cancer therapy (Review)

International Journal of Oncology

Volumn 12, Issue 1, 1998, Pages 141-152

  Decaudin, Didier ^a,b   Marzo, Isabel ^a   Brenner, Catherine ^c   Kroemer, Guido ^a  

^a CNRS   (France)

^b INSTITUT CURIE   (France)

^c UNIVERSITÉ DE TECHNOLOGIE DE COMPIÈGNE   (France)

Author keywords

Mitochondrial transmembrane potential; Permeability transition; Programmed cell death

Indexed keywords

APOPTOSIS; CANCER; CANCER CELL; CANCER CHEMOTHERAPY; HUMAN; MITOCHONDRION; PRIORITY JOURNAL; REVIEW; ANIMAL; DRUG EFFECT; INTRACELLULAR MEMBRANE; METABOLISM; NEOPLASM; PATHOLOGY; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENT; PROTEIN BCL 2;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; HUMANS; INTRACELLULAR MEMBRANES; MITOCHONDRIA; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION;

EID: 0031974274     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.12.1.141     Document Type: Review

References (159)

1. Harmon BV: An ultrastructural study of spontaneous cell death in a mouse mastocytoma with particular reference to dark cells. J Pathol 153: 345-355, 1987.
2. Sarraf CE and Bowen ID: Proportions of mitotic and apoptotic cells in a range of untreated experimental tumours. Cell Tissue Kinet 21: 45-49, 1988.
3. Searle J, Collins DJ, Harmon B and Kerr JFR: The spontaneous occurrence of apoptosis in squamous carcinomas of the uterine cervix. Pathology 5: 163-169, 1973.
4. Kerr JFR and Searle J: A suggested explanation for the paradoxically slow growth rate of basal-cell carcinomas that contain numerous mitotic figures. J Pathol 107: 41-44, 1972.
5. Gobé GC, Axelsen RA and Searle JW: Cellular events in experimental unilateral ischemic renal atrophy and in regeneration after contralateral nephrectomy. Lab Invest 63: 770-779, 1990.
6. 2+ concentration and DNA fragmentation. Cancer Res 52: 1342-1346, 1992.
7. Wright SC, Kumar P, Tam AW, Shen N, Varma M and Larrick JW: Apoptosis and DNA fragmentation precede TNF-induced cytolysis in U937 cells. J Cell Biochem 48: 344-355, 1992.
8. Curson C and Weedon D: Spontaneous apoptosis in basal cell carcinomas. J Cutaneous Pathol 6: 432-437, 1979.
9. Kerr JFR, Wyllie AH and Currie AR: Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 26: 239-257, 1972.
10. 2+ concentration. Arch Biochem Biophys 269: 365-370, 1989.
11. Jacobson MD, Burne JF and Raff MC: Programmed cell death and Bcl-2 protection in the absence of a nucleus. EMBO J 13: 1899-1910, 1994.
12. Schulze-Osthoff K, Walczak H, Droge W and Krammer PH: Cell nucleus and DNA fragmentation are not required for apoptosis. J Cell Biol 127: 15-20, 1994.
13. Kroemer G, Petit PX, Zamzami N, Vayssière J-L and Mignotte B: The biochemistry of apoptosis. FASEB J 9: 1277-1287, 1995.
14. Kroemer G, Zamzami N and Susin SA: Mitochondrial control of apoptosis. Immunol Today 18: 44-51, 1997.
15. Kroemer G: The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nat Med 3: 614-620, 1997.
16. Zamzami N, Hirsch T, Dallaporta B, Petit PX and Kroemer G: Mitochondrial implication in accidental and programmed cell death: apoptosis and necrosis. J Bioenerg Biomembrane 29: 185-193, 1997.
17. Penninger J and Kroemer G: Molecular and cellular mechanisms of lymphocyte apoptosis. Adv Immunol (In press).
18. Zamzami N, Marchetti P, Castedo M, Zanin C, Vayssière J-L, Petit PX and Kroemer G: Reduction in mitochondrial potential constitutes an early irreversible step of programmed lymphocyte death in vivo. J Exp Med 181: 1661-1672, 1995.
19. Zamzami N, Marchetti P, Castedo M, Decaudin D, Macho A, Hirsch T, Susin SA, Petit PX, Mignotte B and Kroemer G: Sequential reduction of mitochondrial transmembrane potential and generation of reactive oxygen species in early programmed cell death. J Exp Med 182: 367-377, 1995.
20. Macho A, Castedo M, Marchetti P, Aguilar JJ, Decaudin D, Zamzami N, Girard PM, Uriel J and Kroemer G: Mitochondrial dysfunctions in circulating T lymphocytes from human immunodeficiency virus-1 carriers. Blood 86: 2481-2487, 1995.
21. Castedo M, Macho A, Zamzami N, Hirsch T, Marchetti P, Uriel J and Kroemer G: Mitochondrial perturbations define lymphocytes undergoing apoptotic depletion in vivo. Eur J Immunol 25: 3277-3284, 1995.
22. Marchetti P, Susin SA, Decaudin D, Gamen S, Castedo M, Hirsch T, Zamzami N, Naval J, Senik A and Kroemer G: Apoptosis-associated derangement of mitochondrial function in cells lacking mitochondrial DNA. Cancer Res 56: 2033-2038, 1996.
23. Zamzami N, Marchetti P, Castedo M, Hirsch T, Susin SA, Masse B and Kroemer G: Inhibitors of permeability transition interfere with the disruption of the mitochondrial transmembrane potential during apoptosis. FEBS Lett 384: 53-57, 1996.
24. Castedo M, Hirsch T, Susin SA, Zamzami N, Marchetti P, Macho A and Kroemer G: Sequential acquisition of mitochondrial and plasma membrane alterations during early lymphocyte apoptosis. J Immunol 157: 512-521, 1996.
25. Marchetti P, Castedo M, Susin SA, Zamzami N, Hirsch T, Haeffner A, Hirsch F, Geuskens M and Kroemer G: Mitochondrial permeability transition is a central coordinating event of apoptosis. J Exp Med 184: 1155-1160, 1996.
26. Zamzami N, Susin SA, Marchetti P, Hirsch T, Gómez-Monterrey I, Castedo M and Kroemer G: Mitochondrial control of nuclear apoptosis. J Exp Med 183: 1533-1544, 1996.
27. Susin SA, Zamzami N, Castedo M, Hirsch T, Marchetti P, Macho A, Daugas E, Geuskens M and Kroemer G: Bcl-2 inhibits the mitochondrial release of an apoptogenic protease. J Exp Med 184: 1331-1342, 1996.
28. Marchetti P, Hirsch T, Zamzami N, Castedo M, Decaudin D, Susin SA, Masse B and Kroemer G: Mitochondrial permeability transition triggers lymphocyte apoptosis. J Immunol 157: 4830-4836, 1996.
29. Marchetti P, Zamzami N, Susin SA, Patrice PX and Kroemer G: Apoptosis of cells lacking mitochondrial DNA. Apoptosis 1: 119-125, 1996.
30. Macho A, Decaudin D, Castedo M, Hirsch T, Susin SA, Zamzami N and Kroemer G: Chloromethyl-X-rosamine is an aldehyde-fixable potential-sensitive fluorochrome for the detection of early apoptosis. Cytometry 25: 333-340, 1996.
31. Susin SA, Zamzami N and Kroemer G: The cell biology of apoptosis: evidence for the involvement of mitochondria. Apoptosis 1: 231-242, 1996.
32. Decaudin D, Geley S, Hirsch T, Castedo M, Marchetti P, Macho A, Kofler R and Kroemer G: Bcl-2 and Bcl-XL antagonize the mitochondrial dysfunction preceding nuclear apoptosis induced by chemotherapeutic agents. Cancer Res 57: 62-67, 1997.
33. Kroemer G, Lisardo B, Zamzami P, Hortelano S and Martinez AC: Detection of apoptosis and apoptosis associated alterations. In: The Immunology Methods Manual. Lefkovitz R (ed). Academic Press, pp 1111-1125, 1997.
34. Kroemer G: Mitochondrial implication in apoptosis. Towards an endosymbiotic hypothesis of apoptosis evolution. Cell Death Differ (In press).
35. Marchetti P, Decaudin D, Macho A, Zamzami N, Hirsch T, Susin SA and Kroemer G: Redox regulation of apoptosis: impact of thiol redoxidation on mitochondrial function. Eur J Immunol 27: 289-296, 1997.
36. Macho A, Hirsch T, Marzo I, Marchetti P, Dallaporta B, Susin SA, Zamzami N and Kroemer G: Glutathione depletion is an early and calcium elevation a late event of thymocyte apoptosis. J Immunol 158: 4612-4619, 1997.
37. Susin SA, Zamzami N, Castedo M, Daugas E, Wang H-G, Geley S, Fassy F, Reed J and Kroemer G: The central executioner of apoptosis. Multiple links between protease activation and mitochondria in Fas/Apo-1/CD95- and ceramide-induced apoptosis. J Exp Med 186: 25-37, 1997.
38. Hirsch T, Marchetti P, Susin SA, Dallaporta B, Zamzami N, Marzo I, Geuskens M and Kroemer G: The apoptosis-necrosis paradox. Apoptogenic proteases activated after mitochondrial permeability transition determine the mode of cell death. Oncogene 15: 1573-1582, 1997.
39. Hortelano S, Dallaporta B, Zamzami N, Hirsch T, Susin SA, Marzo I, Bosca L and Kroemer G: Nitric oxide induces apoptosis via triggering mitochondrial permeability transition. FEBS Lett 410: 373-377, 1997.
40. Susin SA, Zamzami N, Larochette N, Dallaporta B, Marzo I, Brenner C, Hirsch T, Petit PX, Geuskents M and Kroemer G: A cytofluorometric assay of nuclear apoptosis induced in a cell-free system. Application to ceramide-induced apoptosis. Exp Cell Res (In press).
41. Petit PX, Le Coeur H, Zorn E, Dauguet C, Mignotte B and Gougeon ML: Alterations of mitochondrial structure and function are early events of dexamethasone-induced thymocyte apoptosis. J Cell Biol 130: 157-167, 1995.
42. Cossarizza A, Franceschi C, Monti D, Salvioli S, Bellesia E, Rivabene R, Biondo L, Rainaldi G, Tinari A and Malorni W: Protective effect of N-acetylcysteine in tumor necrosis factor-alpha-induced apoptosis in U937 cells: the role of mitochondria. Exp Cell Res 220: 232-240, 1995.
43. Martin SJ, Newmeyer DD, Mathisa S, Farschon DM, Wang HG, Reed JC, Kolesnick RN and Green DR: Cell-free reconstitution of Fas-, UV radiation- and ceramide-induced apoptosis. EMBO J 14: 5191-5200, 1995.
44. Pastorino JG, Simbula G, Yamamoto K, Glascott PAJ, Rothman RJ and Farber JL: The cytotoxicity of tumor necrosis factor depends on induction of the mitochondrial permeability transition. J Biol Chem 271: 29792-29799, 1996.
45. Liu X, Kim CN, Yang J, Jemmerson R and Wang X: Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome C. Cell 86: 147-157, 1996.
46. Xiang J, Chao DT and Korsmeyer SJ: Bax-induced cell death may not require interleukin 1beta-converting enzyme-like proteases. Proc Natl Acad Sci USA 93: 14559-14563, 1996.
47. Boise LH and Thompson CB: Bcl-XL can inhibit apoptosis in cells that have undergone Fas-induced protease activation. Proc Natl Acad Sci US A 94: 3759-3764, 1997.
48. Yang J, Liu X, Bhalla K, Kim CN, Ibrado AM, Cai J, Peng T-I, Jones DP and Wang X: Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science 275: 1129-1132, 1997.
49. Kluck RM, Bossy-Wetzel E, Green DR and Newmeyer DD: The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science 275: 1132-1136, 1997.
50. Kim CN, Wang XD, Huang Y, Ibrado AM, Liu L, Fang GF and Bhalla K: Overexpression of Bcl-x(L), inhibits Ara-C-induced mitochondrial loss of cytochrome c and other perturbations that activate the molecular cascade of apoptosis. Cancer Res 57: 3115-3120, 1997.
51. Polyak K, Xia Y, Zweier JL, Kinzler KW and Vogelstein B: A model for p53-induced apoptosis. Nature 389: 300-305, 1997.
52. Zoratti M and Szabò I: The mitochondrial permeability transition. Biochim Biophys Acta - Rev Biomembrane 1241: 139-176, 1995.
53. Bernardi P and Petronilli V: The permeability transition pore as a mitochondrial calcium release channel; a critical appraisal. J Bioenerg Biomembrane 28: 129-136, 1996.
54. Bernardi P: The permeability transition pore. Control points of a cyclosporin A-sensitive mitochondrial channel involved in cell death. Biochim Biophys Acta Bioenerget 1275: 5-9, 1996.
55. Ichas F, Jouavill LS and Mazat J-P: Mitochondria are excitable organelles capable of generating and conveying electric and calcium currents. Cell 89: 1145-1153, 1997.
56. Beutner G, Rück A, Riede B, Welte W and Brdiczka D: Complexes between kinases, mitochondrial porin, and adenylate translocator in rat brain resemble the permeability transition pore. FEBS Lett 396: 189-195, 1996.
57. 2+. Biochemistry 35: 8483-8488, 1996.
58. Nicolli A, Basso E, Petronilli V, Wenger RM and Bernardi P: Interactions of cyclophilin with mitochondrial inner membrane and regulation of the permeability transition pore, a cyclosporin A-sensitive channel. J Biol Chem 271: 2185-2192, 1996.
59. Halestrup AP, Woodfield K-Y and Connern CP: Oxidative stress, thiol reagents, and membrane potential modulate the mitochondrial permeability transition by affecting nucleotide binding to the adenine nucleotide translocator. J Biol Chem 272: 3346-3354, 1997.
60. Newmeyer DD, Farschon DM and Reed JC: Cell-free apoptosis in Xenopus egg extracts: inhibition by Bcl-2 and requirement for an organelle fraction enriched in mitochondria. Cell 79: 353-364, 1994.
61. Ellerby HM, Martin SJ, Ellerby LM, Naiem SS, Rabizadeh S, Salvese GS, Casiano CA, Cashman NR, Green DR and Bredesen DE: Establishment of a cell-free system of neuronal apoptosis: comparison of premitochondrial, mitochondrial, and postmitochondrial phases. J Neurosci 17: 6165-6178, 1997.
62. Liu X, Zou H, Slaughter C and Wang X: DFF, a heterodimeric protein that functions downstream of caspase 3 to trigger DNA fragmentation during apoptosis. Cell 89: 175-184, 1997.
63. Zhou H, Henzel WJ, Liu X, Lutschg A and Wang X: Apaf-1, a human protein homologous to C. elegans Ced-4, participates in cytochrome c-dependent activation of caspase-3. Cell 90: 405-413, 1997.
64. Geley S, Hartmanen BL, Hala M, Strasser-Wozak EMC, Kapelari K and Kofler R: Resistance to glucocorticoid-induced apoptosis in human T-cell acute lymphoblastic leukemia CEM-C1 cells is due to insufficient glucocorticoid receptor expression. Cancer Res 56: 5033-5038, 1996.
65. Geley S, Hartmann BL and Kofler R: Ceramides induce a form of apoptosis in human acute lymphoblastic leukemia cells that is inhibited by Bcl-2, but not by CrmA. FEBS Lett 400: 15-18, 1997.
66. Shimizu S, Eguchi Y, Kamiike W, Waguri S, Uchiyama Y, Matsuda H and Tsujimoto Y: Bcl-2 blocks loss of mitochondrial membrane potential while ICE inhibitors act at a different step during inhibition of death induced by respiratory chain inhibitors. Oncogene 13: 21-29, 1996.
67. Kharbanda S, Pandey P, Schofield L, Israels S, Roncinske R, Yoshida K, Bharti A, Yan Z-M, Saxena S, Weichselbaum R, Nalin C and Kufe D: Role for Bcl-XL as an inhibitor of cytosolic cytochrome c accumulation in DNA damage-induced apoptosis. Proc Natl Acad Sci USA 94: 6939-6942, 1997.
68. Murphy AN, Bredesen DE, Cortopassi G, Wang E and Fiskum G: Bcl-2 potentiates the maximal calcium uptake capacity of neural cell mitochondria. Proc Natl Acad Sci USA 93: 9893-9898, 1996.
69. Reed JC: Double identity for proteins of the Bcl-2 family. Nature 387: 773-776, 1997.
70. Kantrow SP and Piantadosi CA: Release of cytochrome c from liver mitochondria during permeability transition. Biochem Biophys Res Commun 232: 669-671, 1997.
71. Tsujimoto Y and Croce CM: Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc Natl Acad Sci USA 83: 5214-5218, 1986.
72. Allsopp TE, Wyatt S, Paterson HF and Davies AM: The protooncogene Bcl-2 can selectively rescue neurotrophic factor-dependent neurons from apoptosis. Cell 73: 295-307, 1993.
73. Nun̄ez G, London L, Hockenbery D, Alexander M, McKearn JP and Korsmeyer SJ: Deregulated Bcl-2 gene expression selectively prolongs survival of growth factor-deprived hemopoietic cell lines. J Immunol 144: 3602-3610, 1990.
74. Sentman CL, Shutter JR, Hockenbery D, Kanagawa O and Korsmeyer SJ: Bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes. Cell 67: 881-888, 1991.
75. Hollstein M, Sidransky D, Vogelstein B and Harris C: p53 mutations in human cancers. Science 253: 49-52, 1991.
76. Harris CC and Hollstein M: Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 329: 1318-1327, 1993.
77. Malkin D, Li FP, Strong LC, Fraumeni JF Jr, Nelson CE, Kim DH, Kassel J, Gryka MA, Bishoff FZ, M.A. T and Friend SH: Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250: 1233-1238, 1990.
78. Srivastava S, Zou ZQ, Pirollo K, Blattner WA and Chang EH: Germ-line transmission of a mutated p53 gene in a cancerprone family with Li-Fraumeni syndrome. Nature 348: 747-749, 1990.
79. Rieux-Laucat F, Le Deist F, Hivroz C, Roberts IAG, Debatin KM, Fischer A and De Villartay JP: Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 268: 1347-1349, 1995.
80. Fisher GH, Rosenberg FJ, Straus SE, Dale JK, Middelton LA, Lin AY, Strober W, Lenardo MJ and Puck JM: Dominant interfering fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 81: 935-946, 1995.
81. Bettinardi A, Brugnoni D, Quiros-Roldan E, Malagoli A, Lagrutta S, Correra A and Notarangelo LD: Missense mutations in the fas gene resulting in autoimmune lymphoproliferative syndrome: a molecular and immunological analysis. Blood 89: 902-909, 1997.
82. Sneller MC, Wang J, Dale JK, Strober W, Middleton LA, Choi Y, Fleisher TA, Lim MS, Jaffe ES, Puck JM, Lenardo MJ and Straus SE: Clinical, immunologic, and genetic features of an autoimmune lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis. Blood 89: 1341-1348, 1997.
83. Rowley JD: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243: 290-293, 1973.
84. McGahon A, Bissonnette R, Schmitt M, Cotter KM, Green DR and Cotter TG: BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptosic cell death. Blood 83: 1179-1187, 1994.
85. Lotem J and Sachs L: Regulation by bcl-2, c-myc, and p53 of susceptibility to induction of apoptosis by heat shock and cancer chemotherapy compounds in differentiation-competent and -defective myeloid leukemic cells. Cell Growth Differ 4: 41-47, 1993.
86. Miyashita T and Reed JC: Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 81: 151-157, 1993.
87. Ohmori T, Podack ER, Nishio K, Takahashi M, Miyahara Y, Takeda Y, Kubota N, Funayama Y, Ogasawara H, Ohira T, Ohta S and Saijo N: Apoptosis of lung cancer cells caused by some anti-cancer agents (MMC, CPT-11, ADM) is inhibited by Bcl-2. Biochem Biophys Res Commun 192: 30-36, 1993.
88. Sumantran VN, Ralovega MW, Nunez G, Clarke MS and Wicha MS: Overexpression of Bcl-XS sensitizes MCF-7 cells to chemotherapy-induced apoptosis. Cancer Res 55: 2507-2510, 1995.
89. Krajewski S, Blomqvist C, Franssila K, Krajewska M, Wasenius VM, Niskanen E, Nordling S and Reed JC: Reduced expression of proapoptotic gene Bax is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res 55: 4471-4478, 1995.
90. Eliopoulos AG, Kerr DJ, Herod J, Hodkins L, Krajewski S, Reed JC and Young LS: The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2. Oncogene 11: 1217-1228, 1995.
91. Fan S, Smith ML, Rivet DJ II, Duba D, Zhan Q, Kohn KW, Fornace AJ and O'Connor PM: Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res 55: 1649-1654, 1995.
92. Lowe SW, Schmitt EM, Smith SW, Osborne BA and Jack T: p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362: 847-849, 1993.
93. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE and Jacks T: p53 status and the efficacy of cancer therapy in vivo. Science 266: 807-810, 1994.
94. Momand J, Zambetti GP, Olson DC, George D and Levine AJ: The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69: 1237-1245, 1992.
95. Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW and Vogelstein B: Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 362: 857-859, 1993.
96. Kondo S, Barnett GH, Hara H, Morimura T and Takeuchi J: MDM2 protein confers the resistance of a human glioblastoma cell line to cisplatin-induced apoptosis. Oncogene 10: 2001-2006, 1995.
97. Bedi A, Barber JP, Bedi GC, El-Deiry WS, Sidransky D, Vala MS, Akhrtar AJ, Hilton J and Jones RJ: BCL-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: a mechanism of resistance to multiple anti cancer agents. Blood 86: 1158, 1995.
98. Doroshow JH: Prevention of doxorubicin-induced killing of MCF-7 human breast cancer cells by oxygen radical scavengers and iron chelating agents. Biochem Biophys Res Commun 135: 330-337, 1986.
99. Doroshow JH, Akman S, Chu F-F and Esworthy S: Role of the peroxidase cycle in the cytotoxicity of the anticancer quinones. Pharmacol Ther 47: 359-370, 1990.
100. Sinha BK, Katki AG, Batist G, Cowan KH and Myers CE: Differential formation of hydroxyl radicals by adriamycin in sensitive and resistant MCF-7 human breast tumor cells: implication for the mechanism of action. Biochemistry 26: 3776-3781, 1987.
101. Van Maanen JMS, De Ruiter C, Koostra PR, et al: Free radical formation from the antineoplastic agent VP-16-213. Free Radical Res Commun 1: 263-272, 1986.
102. Costantini P, Chernyak BV, Petronilli V and Bernardi P: Modulation of the mitochondrial permeability transition pore by pyridine nucleotides and dithiol oxidation at two separate sites. J Biol Chem 271: 6746-6751, 1996.
103. Klingenberg M: The ADP-ATP translocation in mitochondria, a membrane potential controlled transport. J Membrane Biol 56: 97-105, 1980.
104. Bose R, Verheij M, Haimovitz-Friedman A, Scotto K, Fuks Z and Kolesnik R: Ceramide synthase mediated daunorubicin-induced apoptosis: an alternative mechanism for generating death signals. Cell 82: 405-414, 1995.
105. Jaffrézou J-P, Levade T, Bettaïeb A, Andrieu N, Bezombes C, Maestre N, Vermeersch S, Rousse A and Laurent G: Daunorubicin-induced apoptosis: triggering of ceramide generation through sphingomyelin hydrolysis. EMBO J 15: 2417-2424, 1996.
106. Testi R: Sphingomyelin breakdown and cell fate. Trends Biochem Sci 21: 468-471, 1996.
107. Paumen MB, Ishida Y, Muramatsu M, Yamamoto M and Honjo T: Inhibition of carnitine palmitoyltransferase I augments sphingolipid synthesis and palmitate-induced apoptosis. J Biol Chem 272: 3324-3329, 1997.
108. García-Ruiz C, Colell A, Marí M, Morales A and Fernández-Checa JC: Direct effect of ceramide on the mitochondrial electron transport chain leads to the generation of reactive oxygen species. J Biol Chem 272: 11369-11377, 1997.
109. Quillet-Mary A, Jaffrezou JP, Mansat V, Bordier C, Naval J and Laurent G: Implication of mitochondrial hydrogen peroxide generation in ceramide-induced apoptosis. J Biol Chem 272: 21388-21395, 1997.
110. De Maria R, Lenti L, Malisan F, D'Agostino F, Tomassini B, Zeuner A, Rippo MR and Testi R: Requirement for GD3 ganglioside in CD95- and ceramide-induced apoptosis. Science 277: 1652-1655, 1997.
111. Miyashita T, Krajewsji S, Krajewska M, Wang HG, Lin HK, Liebermann DA, Hoffman B and Reed JC: Tumor suppressor p53 is a regulator of bcl-2 and box gene expression in vitro and in vivo. Oncogene 9: 1799-1805, 1994.
112. Miyashita T and Reed JC: Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80: 293-299, 1995.
113. Brady HJM, Salomons GS, Bobeldijk RC and Berns AJM: T cells from bax alpha transgenic mice show accelerated apoptosis in response to stimuli but do not show restored DNA damage-induced cell death in the absence of p53. EMBO J 15: 1221-1230, 1996.
114. Haldar S, Jena N and Croce CM: Inactivation of Bcl-2 by phosphorylation. Proc Natl Acad Sci USA 92: 4507-4511, 1995.
115. Haldar S, Chintapalli J and Croce CM: Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res 56: 1253-1255, 1996.
116. Blagosklonny MV, Schulte T, Nguyen P, Trepel J and Neckers LM: Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway. Cancer Res 56: 1851-1854, 1996.
117. Blagosklonny MV, Giannakakou P, Eldeiry WS, Kingston DGI, Higgs PI, Neckers L and Fojo T: Raf-1/bcl/-2 phosphorylation: a step from microtubule damage to cell death. Cancer Res 57: 130-135, 1997.
118. Evtodienki YV, Teplova VV, Sidashi SS, Ichas F and Mazat J-P: Microtubule-active drugs suppress the closure of the permeability transition pore in tumour mitochondria. FEBS Lett 393: 86-88, 1996.
119. Chen LB: Mitochondrial membrane potential in living cells. Annu Rev Cell Biol 4: 155-181, 1988.
120. Murphy MP: Selective targeting of bioactive compounds to mitochondria. Trends Biotech 15: 326-330, 1997.
121. Hennet T, Bertoni G, Richter C and Peterhans E: Expression of BCL-2 protein enhances the survival of mouse fibrosarcoid cells in tumor necrosis factor-mediated cytotoxicity. Cancer Res 53: 1456-1460, 1993.
122. Shan X, Jones DP, Hashmi M and Anders MW: Selective depletion of mitochondrial glutathione concentrations by (R,S)-3-hydroxy-4-pentenoate potentiates oxidative cell death. Chem Res Toxicol 6: 75-81, 1993.
123. Sun XC, Wong JR, Song KL, Hu JL, Garldi KD and Chen LB: AA1, a newly synthesized monovalent lipophilic cation, expresses potent in vivo antitumor-activity. Cancer Res 54: 1465-1471, 1994.
124. Sun XC, Wong JR, Song KL and Chen LB: Anticarcinoma activity of a novel drug, 3-ethyl-3′-methylthitelluracarbocyanine iodide (TE), a tellurium-containing cyanine targeted at mitochondria. Clin Cancer Res 2: 1335-1340, 1996.
125. Weisberg EL, Koya K, Modica-Napolitano H, Li Y and Chen LB: In vivo administration of MKT-077 causes partial yet reversible impairment of mitochondrial function. Cancer Res 56: 551-555, 1996.
126. Modica-Napolitano JS, Koya K, Weisberg E, Brunelli BT, Li Y and Chen IB: Selective damage to carcinoma mitochondria by the rhodacyanine MKT-077. Cancer Res 56: 544-550, 1997.
127. Koya K, Li Y, Wang H, Ukai T, Tatsuta N, Kawakami M, Shishido T and Chen LB: MKT-077, a novel thodacyanine dye in clinical trials, exhibit anticarcinoma activity in preclinical studies based on selective mitochondrial accumulation. Cancer Res 56: 538-543, 1997.
128. Manetta A, Gamboa G, Nassari A, Podnos YD, Emma D, Dorion G, Rawling L, Carpenter PM, Bustamante A, Patel J and Rideout D: Novel phosphinium salts display in vitro and in vivo cytotoxic activity against human ovarian cancer cell lines. Gynecol Oncol 60: 203-212, 1996.
129. Brown J, Higo H, McKalip A and Herman B: Human papilloma-virus (HPV) 16 E6 sensitizes cells to atractyloside-induced apoptosis: role of p53, ICE-like proteases and the mitochondrial permeability transition. J Cell Biochem 66: 245-255, 1997.
130. Pastorino JG, Simbula G, Gilfor E, Hoek JB and Farber JL: Protoporphyrin IX, an endogenous ligand of the peripheral benzodiazepin receptor, potentiates induction of the mitochondrial permeability transition and the killing of culture hepatocytes by rotenone. J Biol Chem 269: 31041-31046, 1994.
131. Sattler M, Liang H, Nettesheim D, Meadows RP, Harlan JE, Eberstadt M, Yoon HS, Shuker SB, Chang BS, Minn AJ, Thompson CB and Fesik SW: Structure of Bcl-x(L)-Bak peptide complex: recognition between regulators of apoptosis. Science 275: 983-986, 1997.
132. Rawadi G, Roman-Roman S, Castedo M, Dutilleul V, Susin S, Marchetti P and Kroemer G: Effects of Mycoplasma fermentons on the myelomonocytic lineage. Different molecular entities with cytokine-inducing and cytocidal properties. J Immunol 156: 670-678, 1996.
133. Fournel S, Genestier L, Robinet E, Flacher M and Revillard JP: Human T cells require IL-2 but not G(1)/S transition to acquire susceptibility to fas-mediated apoptosis. J Immunol 157: 4309-4315, 1996.
134. Sun J, Chen Y, Zhou M, Li MT and Ge ZL: Mitochondrial alterations in CHO cells exposed to X-ray after transfecting with human MnSOD cDNA. Med Sci Res 25: 81-84, 1997.
135. Poot M, Gibson LL and Singer VL: Detection of apoptosis live cells by Mito Tracker(™) red CMXRos and SYTO dye flow cytometry. Cytometry 27: 358-364, 1997.
136. Backway KL, Mcculloch EA, Chow S and Hedley DW: Relationships between the mitochondrial permeability transition and oxidative stress during ara-C toxicity. Cancer Res 57: 2446-2451, 1997.
137. Ceruti S, Barbieri D, Veronese E, Cattabeni F, Cossarizza A, Giammarioli AM, Malorni W, Franceschi C and Abbracchio MP: Different pathways of apoptosis revealed by 2-chloro-adenosine and deoxy-D-ribose in mammalian astroglial cells. J Neurosci Res 47: 372-383, 1997.
138. Medina V, Edmonds B, Young GP, James R, Appleton S and Zalewski PD: Induction of caspase-3 protease activity and apoptosis by butyrate and trichostatin A (inhibitors of histone deacetylase): dependence on protein synthesis and synergy with a mitochondrial/cytochrome c-dependent pathway. Cancer Res 57: 3697-3708, 1997.
139. Nocentini S, Moreno G, Petit PX, Guggiari M, Salet C, Demerseman P and Dodin G: Induction of mitochondrial dysfunction and apoptosis in HeLa cells by bis-pyridinium oximes, a newly synthesized family of lipophilic biscations. Biochem Pharmacol 53: 1543-1552, 1997.
140. Shidoji Y, Nakamura N, Moriwaki H and Muto Y: Rapid loss in the mitochondrial membrane potential during geranylgeranoic acid-induced apoptosis. Biochem Biophys Res Commun 230: 58-63, 1997.
141. Mancini M, Anderson BO, Caldwell E, Sedghinasab M, Paty PB and Hockenbery DM: Mitochondrial proliferation and paradoxical membrane depolarization during terminal differentiation and apoptosis in a human colon carcinoma cell line. J Cell Biol 138: 449-469, 1997.
142. 2+ depletion prevents anoxic death of hepatocytes by inhibiting mitochondrial permeability transition. Am J Physiol 268: C676-C685,1995.
143. Schinder AF, Olson EC, Spitzer NC and Montai M: Mitochondrial dysfunction is a primary event in glutamate neurotoxicity. J Neurosci 16: 6125-6133, 1996.
144. Waring P and Beaver J: Cyclosporin A rescues thymocytes from apoptosis induced by very low concentrations of thapsigargin: effects on mitochondrial function. Exp Cell Res 227: 264-276, 1996.
145. Beaver JP and Waring P: Thapsigargin induces mitochondrial dysfunction and apoptosis in the mastocytoma P815 cell line and in mouse thymocytes. Cell Death Differ 3: 415-424, 1996.
146. Arora AS, Jones BJ, Patel TC, Bronk SF and Gores GJ: Ceramide induces hepatocyte cell death through disruption of mitochondrial function in the rat. Hepatology 25: 958-963, 1997.
147. Costantini P, Petronilli V, Colonna R and Bernardi P: On the effects of paraquat on isolated mitochondria. Evidence that paraquat causes opening of the cyclosporin A-sensitive permeability transition pore synergistically with nitric oxide. Toxicology 99: 77-88, 1995.
148. Hoyt KR, Gallagher AJ, Hastings TG and Reynolds IJ: Characterization of hydrogen peroxide toxicity in cultured rat forebrain neurons. Neurochem Res 22: 333-340, 1997.
149. Kass GEN, Juedes MJ and Orrenius S: Cyclosporin A protects hepatocytes against prooxidant-induced cell killing. Biochem Pharmacol 44: 1995-2003, 1992.
150. Imberti R, Nieminen AL, Herman B and Lemasters JJ: Mitochondrial and glycolytic dysfunction in lethal injury to hepatocytes by t-butylhydroperoxide: protection by fructose, cyclosporin A and trifluoperazine. J Pharmacol Exp Ther 265: 392-400, 1993.
151. Zahrebelski G, Nieminen AL, Alghoul K, Quian T, Herman B and Lemasters JJ: Progression of subcellular changes during chemical hypoxia to cultured rat hepatocyes: a laser scanning confocal microscopic study. Hepatology 21: 1361-1372, 1995.
152. Nieminen AL, Byrne AM, Herman B and Lemasters JI: Mitochondrial permeability transition induced by t-BuOOH: NAD(P)H and reactive oxygen species. Am J Physiol 41: C1286-C1294, 1997.
153. Kristal BS, Park BK and Yu BP: 4-hydroxyhexenal is a potent inducer of the mitochondrial permeability transition. J Biol Chem 271:6033-6038, 1996.
154. Pfciffer DR, Gudz TI, Novgorodov SA and Erdahl WL: The peptide mastoparan is a potent facilitator of the mitochondrial permeability transition. J Biol Chem 270: 4923-4932, 1995.
155. Kupczyk-Subotkowska L, Siahaan TJ, Basile AS, Friedman HS, Higgins PE, Song D and Gallo JM: Modulation of melphalan resistance in glioma cells with a peripheral benzodiazepan receptor ligand melphalan conjugate. J Med Chem 40: 1726-1730, 1997.
156. Hodge T and Colombini M: Regulation of metabolite flux throuch voltage-gating of VDAC channels. J Membrane Biol 157: 271-279, 1997.
157. Connern CP and Halestrap AP: Recruitment of mitochondrial cyclophilin to the mitochondrial inner membrane under conditions of oxidative stress that enhance the opening of a calcium-sensitive non-specific channel. Biochem J 302: 321-324, 1994.
158. Mathupala SP, Rempel A and Perdersen PL: Glucose catabolism in cancer cells: isolation, sequence, and activity of the promoter for type-II hexokinase. J Biol Chem 270: 16918-16925, 1995.
159. Beutner G, Rück A, Riede B and Brdiczka D: Complexes between porin, hexokinase, mitochondrial creatine kinase and adenylate translocator display properties of the permeability transition pore. Implication for regulation of permeability transition by the kinases. Biochim Biophys Acta (In press).